News 2016-08-25
Porton Hosts An Investor Reception, August 25, 2016.
Changshou [Chongqing Metropolitan Region], China, August 25, 2016: Porton proudly hosted a delegation of >50 investment analysts and corporate finance media professionals from the Shenzhen Stock Exchange at its USFDA-inspected production facility in Changshou, The guests were hosted by Porton Vice-Presidents Mr. Richard Tao, Dr. Tim Yu and Mr. Victor Cao and toured the site, which produces and supplies custom drug intermediates and APIs for many of the world’s most well-known and respected pharmaceutical and biotechnology companies.
Others
More
News 2026-08-05
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
Porton Advanced Solutions Ltd. has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA). This milestone qualifies Porton Advanced to undertake commercial contract manufacturing for Cell and Gene Therapy (CGT) products, extending its CDMO services from process development and clinical production through to the commercialization stage.
News 2026-07-08
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
